Target intelligence / Profile preview

EYA transcriptional coactivator and phosphatase 4 (EYA4)

Target
EYA4
Molecular classification
Enzyme (phosphatase: tyrosine and serine/threonine), Transcriptional coactivator, DNA damage response protein
01

Overview

EYA transcriptional coactivator and phosphatase 4 (EYA4) is a dual-function protein with an unusual combination of enzymatic and transcriptional coactivator activities. It belongs to the Eyes absent (EYA) family and exhibits both tyrosine and serine/threonine phosphatase activities in distinct domains, contributing to transcription regulation, DNA damage repair, and organ development, particularly in the ear and heart[1][3][4][5]. EYA4 interacts with and dephosphorylates substrates such as histone H2AX and Polo-like kinase 1 (PLK1), affecting centrosome function and mitotic progression[2]. It promotes the innate immune response and is indispensable for cardiac and auditory integrity, while its dysregulation has been implicated in hereditary hearing loss, dilated cardiomyopathy, and cancer. Mutations or altered regulation of EYA4 are associated with disease, and its unique phosphatase activity is a potential therapeutic target in oncology and immunology, though no established drugs currently exist[1][2][3][4][5].

Other names
Protein phosphatase EYA4Eyes absent homolog 4CMD1JDFNA10dJ78N10.1 (eyes absent)Eyes absent-like protein 4
02

Mechanism of action

Inhibition of phosphatase activity (tyrosine/serine-threonine): Blocks EYA4-dependent dephosphorylation of substrates, disrupts downstream signaling (mitotic progression, gene regulation), induces cell death in cancer models

03

Biological functions

Transcription regulationProtein dephosphorylation (tyrosine and serine/threonine)DNA damage repairCell cycle control (centrosome maturation, mitotic spindle organization)Innate immune response modulationApoptosis regulationOrgan development (ear, heart)
04

Disease associations

Sensorineural hearing loss (DFNA10)Dilated cardiomyopathy 1J (CMD1J)Cancer (oncogenic processes, tumor progression, especially via phosphatase activity)Immune disorders (via innate immune regulation)
05

Safety considerations

Targeting EYA4 may risk perturbing cardiac and auditory function due to its essential role in these tissuesBroad inhibition might impair normal DNA repair, immunity, and developmental pathwaysOff-target effects may arise due to homology with other EYA family members
06

Interacting drugs

None currently established as approved or in clinical use. Experimental inhibitors of EYA phosphatase activity are described in research settings as tools to probe the function and therapeutic potential, but no specific small molecule names with advanced status are reported in the supplied data.
07

Biomarkers

Mutations in EYA4 serve as genetic markers for familial non-syndromic sensorineural hearing loss (DFNA10) and dilated cardiomyopathy 1J (CMD1J)Overexpression or dysregulation could serve as a cancer biomarker in relevant contexts

Beyond the preview

Go deeper on EYA transcriptional coactivator and phosphatase 4 (EYA4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on EYA transcriptional coactivator and phosphatase 4 (EYA4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call